Related Experiment Video

Updated: Jun 8, 2026

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest
04:55

Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest

Published on: May 26, 2023

Cefuroxime pharmacokinetics in pediatric cardiovascular surgery patients undergoing cardiopulmonary bypass

Chad A Knoderer1, Sarah A Saft, Scott G Walker

  • 1Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, Indianapolis, IN, USA.

Journal of Cardiothoracic and Vascular Anesthesia
|September 25, 2010
PubMed

Insights

Pediatric cefuroxime dosing (25-50 mg/kg) is effective for surgical infection prevention during cardiopulmonary bypass (CPB). An additional intraoperative dose via the CPB circuit does not enhance prophylactic benefits.

Area of Science:

  • Pediatric pharmacology
  • Cardiovascular surgery
  • Infectious disease prophylaxis

Background:

  • Cefuroxime is a widely used antibiotic for surgical prophylaxis.
  • Pharmacokinetic data for cefuroxime in pediatric patients undergoing cardiopulmonary bypass (CPB) is limited.
  • Optimizing cefuroxime dosing is crucial for effective surgical-site infection (SSI) prevention in this vulnerable population.

Purpose of the Study:

  • To determine the pharmacokinetic profile of cefuroxime in pediatric patients during CPB.
  • To evaluate the adequacy of standard pediatric cefuroxime dosing regimens for SSI prophylaxis in this setting.
  • To compare the efficacy of single-dose versus two-dose cefuroxime administration during CPB.

Main Methods:

  • Prospective study conducted at a tertiary pediatric teaching hospital.
  • Infants and children undergoing CPB were administered cefuroxime pre-incision and/or in the CPB prime solution.
  • Serial blood samples were analyzed using high-performance liquid chromatography (HPLC); pharmacokinetic modeling was performed using Bayesian estimation.

Main Results:

  • Fifteen pediatric subjects (median age 11 months) were analyzed.
  • Pharmacokinetic parameters included Cmax, systemic clearance (0.050 L/h/kg), volume of distribution (0.213 L/kg), and half-life (3.76 hours).
  • Simulated 8-hour post-dose concentrations were 26.5 mg/L for a two-dose regimen and 16.0 mg/L for a single-dose regimen.

Conclusions:

  • Recommended pediatric cefuroxime doses (25-50 mg/kg) appear adequate for SSI prophylaxis in children undergoing CPB.
  • A second intraoperative dose administered via the CPB circuit does not offer additional prophylactic advantage.
  • Current dosing guidelines are likely sufficient to maintain therapeutic cefuroxime serum concentrations.
Abstract

More Related Videos

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery04:48

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery

Published on: November 28, 2018

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...